AtriCure Inc. (NASDAQ:ATRC) shares were up 3.1% on Tuesday . The stock traded as high as $14.63 and last traded at $14.48, with a volume of 173,192 shares traded. The stock had previously closed at $14.05.

Several research analysts recently weighed in on ATRC shares. JMP Securities started coverage on shares of AtriCure in a research report on Thursday, June 30th. They issued an “outperform” rating and a $25.00 price objective on the stock. Canaccord Genuity restated a “buy” rating on shares of AtriCure in a research report on Tuesday, July 12th. BTIG Research restated a “buy” rating and issued a $19.00 price objective (down from $34.00) on shares of AtriCure in a research report on Wednesday. Zacks Investment Research cut shares of AtriCure from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $20.00 price target (down from $23.00) on shares of AtriCure in a research report on Monday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $20.13.

The stock has a 50-day moving average of $14.87 and a 200 day moving average of $15.80. The stock’s market cap is $482.09 million.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.04. During the same period in the previous year, the firm earned ($0.18) earnings per share. The company had revenue of $39.70 million for the quarter, compared to analysts’ expectations of $39.84 million. The firm’s quarterly revenue was up 21.8% on a year-over-year basis. On average, equities analysts forecast that AtriCure Inc. will post ($1.16) EPS for the current fiscal year.

Several hedge funds and institutional investors recently bought and sold shares of the stock. RS Investment Management Co. LLC boosted its position in AtriCure by 21.1% in the fourth quarter. RS Investment Management Co. LLC now owns 2,679,551 shares of the medical device company’s stock worth $60,129,000 after buying an additional 466,200 shares during the last quarter. Wells Fargo & Company MN boosted its position in AtriCure by 20.2% in the fourth quarter. Wells Fargo & Company MN now owns 659,070 shares of the medical device company’s stock worth $14,789,000 after buying an additional 110,890 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its position in AtriCure by 15.3% in the fourth quarter. Victory Capital Management Inc. now owns 51,647 shares of the medical device company’s stock worth $1,159,000 after buying an additional 6,845 shares in the last quarter.

AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.